leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...979899100101102103104105106107...235236»
  • ||||||||||  Tarlige (mirogabalin) / Daiichi Sankyo, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Journal:  Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer. (Pubmed Central) -  Apr 13, 2022   
    Although the prognosis of unresectable PC is poor, it has been dramatically improved by new chemotherapy treatments, such as the combination of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel...In addition, pregabalin was more effective than duloxetine for CIPN in two RCTs...Therefore, the choice between the two drugs should be determined according to effect and tolerability. Mirogabalin is also used in patients with PC and there is hope it will yield positive outcomes when treating CIPN in the future.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Journal, Real-world evidence:  Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis. (Pubmed Central) -  Apr 13, 2022   
    Mirogabalin is also used in patients with PC and there is hope it will yield positive outcomes when treating CIPN in the future. This retrospective study provides real-world evidence underscoring that anti-EGFR re-exposure strategies might benefit patients independently of the reason for prior discontinuation.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
    Journal, Real-world evidence:  Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. (Pubmed Central) -  Apr 13, 2022   
    Only half of patients aged 75-84 years with a resectable tumor actually underwent resection. Two thirds of patients aged ≥85 years refused chemotherapy, thus underlining the need to expand geriatric assessments.
  • ||||||||||  numidargistat (INCB001158) / Calithera
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) -  Apr 13, 2022   
    P1/2,  N=149, Active, not recruiting, 
    Two thirds of patients aged ≥85 years refused chemotherapy, thus underlining the need to expand geriatric assessments. Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2022 --> Jun 2022
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal, PD(L)-1 Biomarker, IO biomarker:  Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations. (Pubmed Central) -  Apr 12, 2022   
    Tissue microarrays (TMAs) with up to three 1 mm diameter cores per patient were prepared from 117 stage III CRC patients treated with adjuvant fluoropyrimidine/oxaliplatin (FOLFOX) chemotherapy...These findings were supported by results from an independent FOLFOX-treated cohort of 191 stage III CRC patients, where higher PD1- Tregs were associated with an increase overall survival (p = 0.015) for CD3+/CD4+/FOXP3+/PD1-. Overall, compared to single markers, multi-marker classification provided more accurate quantitation of immune cell types with stronger correlations with outcomes.
  • ||||||||||  methotrexate / Generic mfg.
    Review, Journal:  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. (Pubmed Central) -  Apr 12, 2022   
    The quality of evidence for these recommendations was very low. Rationales for these recommendations included: (1) extracorporeal treatments mainly remove drugs in the intravascular compartment, whereas methotrexate rapidly distributes into cells; (2) extracorporeal treatments remove folinic acid; (3) in rare cases where fast removal of methotrexate is required, glucarpidase will outperform any extracorporeal treatment; and (4) extracorporeal treatments do not appear to reduce the incidence and magnitude of methotrexate toxicity.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study). (Pubmed Central) -  Apr 12, 2022   
    Patients given 180 mg of irinotecan and a 400 mg bolus of 5-fluorouracil (5-FU) showed a marked difference in outcome when compared to irinotecan 180 mg given without the 5-FU bolus, with the overall response rate being 28%, a survival time of 6.4 months and progression-free survival time of 4.5 months. The optimum dose of FOLFIRINOX was a dosage combination of oxaliplatin 85 mg/m , irinotecan 180 mg/m , l-leucovorin 400 mg/m  and 5-FU 2,400 mg/m , administered as a continuous 46-h infusion.
  • ||||||||||  oxaliplatin / Generic mfg., capecitabine / Generic mfg.
    Enrollment closed:  PECORINO: Perioperative Chemotherapy in Gastric Cancer (clinicaltrials.gov) -  Apr 12, 2022   
    P2,  N=284, Active, not recruiting, 
    Trial completion date: Oct 2025 --> Oct 2026 | Initiation date: Oct 2021 --> Jul 2022 | Trial primary completion date: May 2023 --> May 2024 Recruiting --> Active, not recruiting
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal:  Organoids derived from neoadjuvant FOLFIRINOX patients recapitulate therapy resistance in pancreatic ductal adenocarcinoma. (Pubmed Central) -  Apr 8, 2022   
    Resistance development in neoadjuvant FOLFIRINOX organoids, recapitulating their primary tumor resistance, suggests continuation of FOLFIRINOX therapy as an adjuvant treatment may not be advantageous for these patients. Gene expression profiles of PDAC organoids identify targetable pathways involved in chemoresistance development upon neoadjuvant FOLFIRINOX treatment, thus opening up combination therapy possibilities.
  • ||||||||||  leucovorin calcium / Generic mfg., l-methylfolate / Generic mfg.
    Review, Journal:  The potential use of folate and its derivatives in treating psychiatric disorders: A systematic review. (Pubmed Central) -  Apr 8, 2022   
    Gene expression profiles of PDAC organoids identify targetable pathways involved in chemoresistance development upon neoadjuvant FOLFIRINOX treatment, thus opening up combination therapy possibilities. Increasing evidence from clinical trials consistently demonstrate folate supplements, especially levomefolic acid or 5-methylfolate, may improve clinical outcomes for certain psychiatric diseases, especially as an adjunct pharmacotherapy with minimal side effects.
  • ||||||||||  Kuvan (sapropterin) / Merck (MSD), BioMarin, Daiichi Sankyo
    Journal:  Disorders of Tetrahydrobiopterin Metabolism: Experience from South India. (Pubmed Central) -  Apr 8, 2022   
    Screening for disorders of biopterin metabolism in patients with hyperphenylalaninemia prevents delayed diagnosis. This study expands the genotype-phenotype spectrum of patients with disorders of tetrahydrobiopterin metabolism from South India.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, HEOR:  Cost-effectiveness of Pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. (Pubmed Central) -  Apr 8, 2022   
    Pembrolizumab received FDA approval in 2020 for first-line treatment of Stage IV MSI-H/dMMR CRC based on significantly longer progression-free survival versus standard of care (SoC, 5-fluorouracil-based therapy with or without bevacizumab or cetuximab)...Pembrolizumab dominated FOLFOX + panitumumab, FOLFOXIRI, and FOLFOXIRI + bevacizumab, and presented ICERs of $35,220 and $276 against XELOX and XELOX + bevacizumab...Results were robust to sensitivity and scenario analyses. Pembrolizumab is highly cost-effective for the first-line treatment of unresectable or metastatic MSI-H/dMMR CRC in the US at a willingness-to-pay threshold of $100,000/QALY.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. (Pubmed Central) -  Apr 7, 2022   
    For patients with borderline resectable metastases, the combination of triplet chemotherapy with 5 fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) offers the best conversion rate. The role of biologic agents such as bevacizumab and EGFR inhibitors in these settings is less clear based on current evidence.
  • ||||||||||  EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
    Trial completion, Enrollment change, Metastases:  Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) -  Apr 7, 2022   
    P1,  N=15, Completed, 
    No abstract available Active, not recruiting --> Completed | N=30 --> 15
  • ||||||||||  EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases:  NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) -  Apr 7, 2022   
    P1/2,  N=2, Completed, 
    Active, not recruiting --> Completed | N=30 --> 15 Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Jun 2021 | Trial primary completion date: Dec 2021 --> Jun 2021
  • ||||||||||  cabiralizumab (BMS-986227) / Ono Pharma, BMS, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date:  A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) -  Apr 7, 2022   
    P2,  N=262, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Jun 2021 | Trial primary completion date: Dec 2021 --> Jun 2021 Trial completion date: Jul 2022 --> Feb 2023 | Trial primary completion date: Jan 2022 --> Aug 2022